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Abstract: 
BACKGROUND  
There is an urgent need to identify biomarkers to guide personalized 
therapy in castration-resistance prostate cancer (CRPC). We aimed to 
clinically qualify androgen receptor (AR) status measurement in plasma 
DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-
chemotherapy CRPC.  
 
METHODS  
We optimised ddPCR assays for AR copy number and mutations and 
retrospectively analysed plasma DNA from patients recruited to one of 
three biomarker protocols with prospectively-collected clinical data. We 
evaluated associations between plasma AR and overall survival (OS) and 
progression-free survival (PFS) in 73 chemotherapy-naïve and 98 post-
docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary 
cohort) and 94 chemotherapy-naïve patients treated with enzalutamide 
(Secondary cohort; PREMIERE trial).  
 
RESULTS  
In the primary cohort, AR gain was observed in 10 (14%) chemotherapy-
naïve and 33 (34%) post-docetaxel patients and associated with worse OS 
(Hazard Ratio (HR), 3.98; 95%CI, 1.74-9.10; p<0.001 and HR, 3.81; 
95%CI, 2.28-6.37; p<0.001 respectively), PFS (HR, 2.18; 95%CI, 1.08-
4.39; p=0.03, and HR, 1.95; 95%CI, 1.23-3.11; p=0.01 respectively) and 
rate of PSA decline ≥50% (Odds ratio (OR), 4.7; 95%CI, 1.17-19.17; 
p=0.035 and OR, 5.0; 95%CI, 1.70-14.91; p=0.003 respectively). AR 
mutations (2105T>A (p.L702H) and 2632A>G (p.T878A)) were observed 
in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-
treated patients and were also associated with worse OS (HR 3.26; 95%CI, 
1.47-not reached; p=0.004). There was no interaction between AR and 
docetaxel status (p=0.83 for OS, p=0.99 for PFS). In the PREMIERE trial, 
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11 patients (12%) with AR gain had worse sPFS (HR, 4.33; 95%CI, 1.94-
9.68; p<0.001), rPFS (HR, 8.06; 95%CI, 3.26-19.93; p<0.001) and OS 
(HR, 11.08; 95%CI, 2.16-56.95; p=0.004). Plasma AR was an independent 
predictor of outcome on multivariate analyses in both cohorts.  
 
CONCLUSION  
Plasma AR status assessment using ddPCR identifies CRPC with worse 
outcome to enzalutamide or abiraterone. Prospective evaluation of 
treatment decisions based on plasma AR is now require 
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ABSTRACT 
BACKGROUND  
There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistance 
prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) status measurement in 
plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. 
 
METHODS 
We optimised ddPCR assays for AR copy number and mutations and retrospectively analysed plasma 
DNA from patients recruited to one of three biomarker protocols with prospectively-collected clinical 
data. We evaluated associations between plasma AR and overall survival (OS) and progression-free 
survival (PFS) in 73 chemotherapy-naïve and 98 post-docetaxel CRPC patients treated with 
enzalutamide or abiraterone (Primary cohort) and 94 chemotherapy-naïve patients treated with 
enzalutamide (Secondary cohort; PREMIERE trial). 
 
RESULTS  
In the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-
docetaxel patients and associated with worse OS (Hazard Ratio (HR), 3.98; 95%CI, 1.74-9.10; p<0.001 
and HR, 3.81; 95%CI, 2.28-6.37; p<0.001 respectively), PFS (HR, 2.18; 95%CI, 1.08-4.39; p=0.03, and 
HR, 1.95; 95%CI, 1.23-3.11; p=0.01 respectively) and rate of PSA decline ≥50% (Odds ratio (OR), 4.7; 
95%CI, 1.17-19.17; p=0.035 and OR, 5.0; 95% CI, 1.70-14.91; p=0.003 respectively). AR mutations 
(2105T>A (p.L702H) and 2632A>G (p.T878A)) were observed in eight (11%) post-docetaxel but no 
chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 
95%CI, 1.47-not reached; p=0.004). There was no interaction between AR and docetaxel status 
(p=0.83 for OS, p=0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse 
sPFS (HR, 4.33; 95%CI, 1.94-9.68; p<0.001), rPFS (HR, 8.06; 95% CI, 3.26-19.93; p<0.001) and OS 
(HR, 11.08; 95%CI, 2.16-56.95; p=0.004). Plasma AR was an independent predictor of outcome on 
multivariate analyses in both cohorts.  
 
CONCLUSION 
Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or 
abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required. 
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Clinical Trial number:NCT02288936 (PREMIERE trial) 
 
Key words: castration-resistant prostate cancer, androgen receptor, plasma DNA, enzalutamide, 
abiraterone, biomarker 
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Key Message 
We clinically qualified AR status in plasma DNA using an optimized multiplex droplet digital PCR assay. 
We studied a primary cohort of 171 pre- and post-docetaxel patients treated with abiraterone or 
enzalutamide and a second cohort of 94 chemotherapy-naïve patients treated with enzalutamide, 
confirming that detection of plasma AR aberrations predicted adverse outcome across the CRPC 
spectrum.  
 
INTRODUCTION 
Inhibition of androgen receptor (AR) signaling with abiraterone or enzalutamide is now standard 
treatment at emergence of castration-resistant prostate cancer (CRPC). However, the duration of 
response is variable and overall survival (OS) in unselected patients is modest despite some patients 
having responses that last several years [1, 2]. There is therefore an urgent need to develop biomarker 
strategies to a priori identify CRPC patients who will derive minimal benefit from AR targeting and offer 
them an alternative treatment paradigm. Testing for plasma Epidermal Growth Factor Receptor (EGFR) 
mutations has FDA clearance for selection of mutant lung cancer patients for EGFR tyrosine kinase 
inhibitors and studies of plasma DNA in multiple indications have suggested clinical utility for monitoring 
of mutations or copy number (CN) gain [3-6]. 
 
Next-generation sequencing (NGS) and PCR-based studies have identified associations between AR 
CN gain detected in plasma and worse outcome with abiraterone or enzalutamide, in predominantly 
post-docetaxel CRPC cohorts [7-12]. AR gene aberrations are rare prior to hormone therapy but occur 
in metastases harvested at rapid warm autopsy from up to 60% of patients [13]. Using NGS on 
sequential plasma samples, we have identified two AR point mutations (2105T>A (p.L702H) and 
2632A>G (p.T878A)) as associating with resistance to abiraterone, shown previously to be activated by 
prednisone or progesterone respectively [7, 8, 14, 15]. For enzalutamide, the 2629T>C (p.F877L) point 
mutation has been reported as a resistance mechanism [16, 17] although a recent study suggested it is 
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very uncommon [12]. Following a well-described roadmap for implementation of a biomarker test into 
routine clinical practice [18], we aimed to optimize a droplet digital PCR (ddPCR) assay that is fit for 
purpose and can be widely implemented on plasma DNA in clinical laboratories. We sought to define 
AR CN and in a separate reaction, AR mutation status: 2105T>A and 2632A>G in patients considered 
for abiraterone and 2629T>C for patients treated with enzalutamide. We then aimed to obtain stage 
one biomarker clinical qualification for associations with clinical outcome on enzalutamide or 
abiraterone in chemotherapy-naïve and post-docetaxel CRPC patients treated in one of three 
biomarker protocols.   
 
MATERIAL AND METHODS 
Study design  
This was a multi-institution analysis of plasma samples collected prospectively in studies with the 
primary aim of biomarker evaluation. The objectives were defined after sample collection but prior to 
plasma analysis. Our first objective was to determine the correlation between ddPCR testing for plasma 
AR and an orthogonal approach, next-generation sequencing (NGS), in samples collected prior to 
starting treatment and after disease progression. Our second objective was to evaluate associations 
between pre-treatment plasma AR and clinical outcome in a primary cohort, representative of both pre- 
and post-docetaxel patients, and test for interactions with prior chemotherapy exposure. As no trial to 
date has randomised patients between first-line enzalutamide or abiraterone and taxanes, we 
combined data from four cohorts of men recruited to two biomarker protocols and defined by treatment 
with enzalutamide or abiraterone and prior chemotherapy status. Our third objective was to test our 
ddPCR assay in a second cohort of chemotherapy-naïve men treated with enzalutamide in the 
PREMIERE trial.  
 
Participants 
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The primary cohort included patients participating in one of two protocols separately approved by the 
Institutional Review Board of the Royal Marsden (RM), London, UK (REC 04/Q0801/6), and Istituto 
Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy (REC 2192/2013). 
Docetaxel in this cohort was only used in the CRPC setting. The second cohort was the PREMIERE 
trial (EudraCT: 2014-003192-28, NCT02288936) that was sponsored and conducted by the Spanish 
Genito-Urinary oncology Group (SOGUG). The trial was approved by the independent review board at 
each participating site. This trial was designed to analyse the predictive value of the gene fusion 
TMPRSS2-ETS in response to enzalutamide in patients with prostate cancer. Exploratory end-points 
included circulating cell-free DNA and circulating tumor cell (CTC) analysis. Data emerging after the 
trial was designed and initiated [7, 19, 20] led the PREMIERE Trial Management Group to prioritize two 
alternative biomarkers for evaluation, namely AR-V7 detected in CTCs as described previously [19] and 
plasma AR. TMPRSS2-ETS analyses are on-going and will be reported elsewhere. Preliminary AR-V7 
data was presented in abstract form at the ESMO 2016 Annual Meeting [21] and will be published 
elsewhere. These analyses were based on the first censor cut-off, date May 2016. A second data 
analysis is planned at a predefined time-point when enough events have occurred to address the 
primary endpoint.  
 
In both cohorts, patients were required to have histologically-confirmed prostate adenocarcinoma 
without neuroendocrine differentiation, progressive disease despite “castration levels” of serum 
testosterone (<50 ng/dL), on-going LHRH analogue treatment or prior surgical castration and no prior 
treatment with enzalutamide or abiraterone. Additional selection criteria by cohort are specified in the 
Supplementary Appendix S1, available at Annals of Oncology online. The choice of therapy in the 
primary cohort was at the discretion of the treating physician, either enzalutamide 160mg once a day or 
abiraterone 1g once a day and prednisone 5mg twice daily. In the PREMIERE trial, all patients received 
enzalutamide 160mg once a day. Treatment in both cohorts was administered continuously until 
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evidence of progression disease or unacceptable toxicity. The studies were conducted in accordance 
with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International 
Conference of Harmonization. Written informed consent was obtained from all patients. 
 
 
 
Procedures 
Peripheral blood samples were collected within 30 days of treatment initiation and plasma aliquots 
stored at -80°C. ddPCR assays were performed as described in detail in Supplementary Appendix S2, 
available at Annals of Oncology online. For each individual sample AR CN was estimated using each of 
the reference genes NSUN3, ElF2C1, and AP3B1 and using ZXDB at Xp11.21 as a control gene to 
determine X chromosome CN. AR mutation detection assays were performed for the AR mutations 
2105T>A (p.L702H), 2632A>G (p.T878A), and 2629T>C (p.F877L) with a limit of detection of 1-2% 
using an input of 2 to 4 ng of DNA. For NGS on plasma and patient-matched germline DNA, we used a 
customized AmpliSeq targeted gene panel including AR, sequenced on an Ion Torrent Personal 
Genome Machine or Proton as described previously [7, 8]. Computational analysis estimating the 
plasma DNA tumor content, AR CN quantitation and point mutation detection (with a sensitivity of 98-
99% depending on position and coverage) was performed as previously [8]. 
 
Serum prostate specific antigen (PSA) was assessed within one week of starting treatment and monthly 
thereafter. Radiographic disease was evaluated with the use of computed tomography and bone scan 
at the time of screening and every 12 weeks on treatment. In the primary cohort, serum lactate 
dehydrogenase (LDH) and alkaline phosphatase (ALP) were also measured within one week of starting 
treatment. In PREMIERE, CTCs were evaluated pre-treatment using the AdnaTest for Prostate Cancer 
(Qiagen GmbH, Germany) as described previously [21].  
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Outcomes 
For the primary cohort, the primary endpoint was OS. The secondary endpoints were progression-free 
survival (PFS) (biochemical and/or radiographic and/or clinical) and PSA response. For PREMIERE, 
the primary endpoint was PSA-PFS (sPFS). Secondary endpoints included radiographic-PFS (rPFS), 
OS and PSA response. OS was calculated from initiation of therapy to death from any cause. Patients 
still alive at time of last follow-up were censored. PFS was calculated from the first day of enzalutamide 
or abiraterone therapy to the date of progression disease or death. Radiographic progression was 
defined using Response Evaluation Criteria in Solid Tumors version 1.1. PSA decline was evaluated 
according to Prostate Cancer Working Group (PCWG2) guidelines [22].  
 
Statistical analyses 
An R script [23] was developed to identify the optimal AR CN cut-point that associated with OS in the 
primary cohort, using maximum log-likelihood as correlative statistics in a multivariable Cox regression 
model by an approach described previously (Supplementary Appendix S3, available at Annals of 
Oncology online) [24]. The process was bootstrapped with 30,000 iterations to provide the measures of 
dispersion. Remaining analyses were conducted using Stata/MP 13.1 for Windows. Time-to-event 
outcomes were evaluated using Kaplan-Meier survivor estimates, log-rank test and univariate and 
multivariable Cox-proportional hazards models. The association of clinically relevant baseline factors 
(previously showed to be associated with prognosis [25, 26] with OS and PFS was examined using a 
univariate Cox regression model. A multivariate Cox regression model was then performed with a 
stepwise procedure to identify the prognostic factors for OS and PFS with a significance level of <0.05 
for entry into the model. All tests were two-sided and an α-error of 5% was considered as significant. 
Odds ratios of PSA response were determined using a 2x2 contingency table and significant 
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differences using Fisher’s exact test. (Supplementary Appendix S3, available at Annals of Oncology 
online).  
 
RESULTS 
Clinical Characteristics of the Primary Cohort 
In the primary cohort, we had 171 men who started treatment with enzalutamide or abiraterone 
between Jan 31, 2011 and June 9, 2016, 73 prior to docetaxel and 98 after. All had received 
bicalutamide. Patient and treatment characteristics at the time of sample collection are detailed in Table 
1.  
 
Analytic Testing of Multiplex Droplet Digital PCR for Determination of Plasma AR Status 
We used an optimized multiplex AR CN ddPCR assay on 2-4ng DNA from all pre-treatment samples 
and an additional 42 samples collected after disease progression. On a further 2-4ng DNA, we tested 
for AR mutations. From patients in the primary cohort with ddPCR data, we had NGS data available 
from our previous publication [8] for 86 samples and we performed NGS on an additional 75 (samples 
described in Supplementary Table S1, available at Annals of Oncology online). We observed a strong 
agreement between NGS and ddPCR for CN quantitation (n=161, Bland-Altman test: mean difference, 
-0.02, 95% CI Limits of agreement, -2.45 to 2.41) (Supplementary Figure S1A and Table S2, available 
at Annals of Oncology online). Estimation of AR mutation allelic frequency by ddPCR also displayed 
strong agreement with NGS (n=60, Bland-Altman test: mean difference -0.001, 95% CI limits of 
agreement, -0.015 to 0.016) with no cases of mutations detected by one approach but not the other 
(Supplementary Figure S1B, available at Annals of Oncology online).  
 
Plasma AR status in the Primary Cohort 
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In our primary cohort, eight post-docetaxel (but no chemotherapy-naïve) abiraterone patients were AR 
point mutation positive prior to treatment (Table 1). We planned to analyse these separately for 
associations with outcome. All four patients with a 2105T>A (p.L702H) mutation had received at least 
six months of treatment with prednisone. We did not detect a 2629T>C (p.F877L) AR point mutation 
prior to treatment or in an additional 26 samples collected after progression on enzalutamide. Using 
maximum likelihood ratio as correlative statistics combined with boot-strapping, we identified an AR CN 
cut-point of 2.01 (interquartile range (IQR), 1.82-2.77 copies) for splitting patients into two distinct 
prognostic groups (Supplementary Figure S2, available at Annals of Oncology online). Use of this cut-
off was also supported by 95.5% concordance between NGS and ddPCR for classifying AR CN status 
(Supplementary Table S2, available at Annals of Oncology online). Overall, 10 (14%) chemotherapy-
naïve and 33 (34%) docetaxel-treated patients had AR gain (Table 1). 
  
Plasma AR Associates with Worse Outcome in the Primary Cohort 
There was a significant association for AR gain and OS in both chemotherapy-naïve (median, 12.40 
months versus not reached; HR, 3.98; 95% CI, 1.74-9.10; p < 0.001) (Figure 1A), and post-docetaxel 
patients (median, 9.51 versus 21.80 months; HR, 3.81; 95% CI, 2.28-6.37; p < 0.001) (Figure 1B). For 
AR mutants in abiraterone-treated, post-docetaxel patients, a significant association with worse survival 
was also seen (median 4.06 months; HR, 3.26; 95% CI, 1.47-not reached; p = 0.004) (Figure 1B). We 
also observed a significant association between PFS and AR gain for chemotherapy-naïve patients 
treated with enzalutamide or abiraterone (median, 7.30 versus 9.20 months; HR, 2.18; 95% CI, 1.08-
4.39; p = 0.03) (Figure 1C) and for post-docetaxel patients (median, 5.00 versus 7.36 months; HR, 
1.95; 95% CI, 1.23-3.11; p = 0.01) (Figure 1D). A trend was seen for AR mutants to have worse PFS 
(median 4.10 months; HR, 2.10; 95% CI, 0.98-4.51; p = 0.057) (Figure 1D). Interactions between AR 
CN and treatment (abiraterone versus enzalutamide) (p = 0.41 for OS and p = 0.11 for PFS) or 
chemotherapy status (p = 0.83 for OS, p = 0.99 for PFS) examined in the Cox models were not 
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significant. We also evaluated the association of AR status with the rate of PSA decline in the 
chemotherapy-naïve and post-docetaxel groups. Chemotherapy-naïve patients with AR gain were 4.7 
times less likely to have a ≥50% decline in PSA (95% CI, 1.17-19.17; p = 0.035) (Figure 1E). Plasma 
AR gain chemotherapy-treated patients were 5.0 times less likely to have a ≥50% decline in PSA (95% 
CI, 1.70-14.91; p = 0.003) (Figure 1F). For the eight AR mutant patients, a trend for a lower rate of 
≥50% PSA decline was seen (odds ratio (OR), 6.3; 95% CI, 0.72-54.59; p = 0.12) (Figure 1F). 
  
Plasma AR Independently Associates with Worse Outcome on Multivariate Analysis in the 
Primary Cohort.  
Plasma AR status and 11 baseline characteristics previously shown to be clinically relevant [25, 26] 
were evaluated by both univariate and multivariate analyses on the whole primary cohort. Plasma AR 
gain or mutant were most significantly associated with OS or PFS (Supplementary Table S3 and Table 
S4 available at Annals of Oncology online). We then performed multivariate analysis with stepwise 
backwards elimination and the sole variables that remained significant were plasma AR status (HR, 
4.10; 95% CI, 2.66-6.35; p < 0.001, and HR, 4.02; 95% CI, 1.87-8.66; p < 0.001, for AR CN and AR 
mutant, respectively, Table 2A) and total plasma DNA concentration for OS and plasma AR status (HR, 
2.06; 95% CI, 1.36-3.12; p = 0.001, and HR, 2.20; 95% CI, 1.03-4.69; p = 0.041, for AR CN and AR 
mutant, respectively), total plasma DNA concentration and ALP levels for PFS (Table 2B).  
 
Plasma AR status in the PREMIERE Cohort 
The PREMIERE trial enrolled 98 patients in 16 sites between February 2015 through November 2015. 
Plasma was collected at study entry before starting enzalutamide from 94 patients who had a median 
follow-up of 10.6 months. Patient characteristics by plasma AR status are described in Table 3A.  
 
Plasma AR Associates with Worse Outcome in the PREMIERE Cohort 
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Similar to our primary cohort pre-chemotherapy population, we observed AR gain in 11 (12%) patients. 
CTCs were detected in 35 patients (37%). AR gain was detected in seven (20%) CTC-positive and four 
(7%) CTC-negative patients (Table 3A). Plasma AR gain was significantly associated with shorter sPFS 
(median, 3.60 versus 15.5 months; HR, 4.33; 95% CI, 1.94-9.68; p < 0.001) (Figure 2A), rPFS (median, 
3.90 months versus not reached; HR, 8.06; 95% CI, 3.26-19.93; p < 0.001) (Figure 2B) and OS 
(medians not reached; HR, 11.08; 95% CI, 2.16-56.95; P = 0.004) (Figure 2C) (Supplementary Table 
S5, available at Annals of Oncology online). Patients with AR gain were less likely to have a ≥50% 
decline in PSA (OR, 4.93; 95% CI, 1.30-18.75; p = 0.025) (Figure 2D).  
 
Plasma AR Independently Associates with Worse Outcome on Multivariate Analysis in the 
PREMIERE Cohort 
On multivariate analysis, the association of AR gain with the primary endpoint of sPFS was 
independent of plasma DNA concentration and the detection of CTCs (HR, 4.32; 95% CI 1.90-9.85; p < 
0.001) (Table 3B). AR gain was also independently associated on multivariate analysis with rPFS (HR, 
5.63; 95% CI, 2.15-14.74; p < 0.001) (Table 3B). 
 
 
DISCUSSION 
Several treatments are available for metastatic CRPC but to date, no approved biomarker to 
personalize therapy. Our analyses of plasma from 265 patients collected in three prospective biomarker 
protocols show that detection of AR CN gain prior to starting enzalutamide or abiraterone is associated 
with decreased OS and PFS regardless of prior chemotherapy status. We excluded samples from 
patient that had prior treatment with enzalutamide or abiraterone, given response rates and duration of 
benefit are very different when used sequentially [27]. Our previous study [8] suggests a similar 
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association between plasma AR and resistance in patients previously treated with enzalutamide or 
abiraterone and this requires further investigation in future studies.  
 
We did not detect AR mutations (p.T878A or p.L702H) in chemotherapy-naïve patients. Our assay 
detects point mutations present in at least 2% of plasma DNA. Greater sensitivity is obtained with 
higher input DNA [28] although the clinical relevance of rarer mutations is uncertain. By using a 
multiplex ddPCR with four carefully selected reference genes, we have designed a robust assay that 
does not over-call gain due to loss in regions involving the reference gene. Our model for estimating the 
likelihood of the AR CN cut-off that best predicts associations with outcome was built with 171 patients. 
We plan to perform a meta-analysis of multiple trials when the data on AR CN acquired from different 
institutions and trials exceeds 1000 patients. We report the absence of an interaction between AR and 
chemotherapy status in non-randomized cohorts.  
 
Detection of AR splice variants in CTCs is also associated with shorter PFS and OS with enzalutamide 
or abiraterone [19, 29].  AR CN is higher in the population with detectable CTCs although AR gain can 
also be observed in CTC-negative patients, accounting for one third of AR gained in the PREMIERE 
cohort. The overlap between AR-V7 positive and plasma AR gained patients and a comparison of the 
two tests in prospective trials is warranted to develop the best biomarker strategy for identifying 
resistant patients. Testing plasma AR status by ddPCR is affordable and can be widely implemented in 
clinical laboratories but does not control for plasma DNA tumor content [7, 8] that may introduce a bias. 
Nonetheless, multivariate analyses confirm that plasma AR by ddPCR provides information on the 
outcome of men starting enzalutamide or abiraterone that is independent of other factors previously 
reported to be prognostic [25, 26, 30].  In keeping with higher response rates to AR targeting in 
chemotherapy-naïve patients, the prevalence of plasma AR aberrations is 10-15% in this setting 
compared to 30-40% post-docetaxel. As our study is single arm, the associations we report are 
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prognostic although the association with PSA decline rate suggests plasma AR CN could identify 
patients resistant to enzalutamide or abiraterone. The aims of our study were defined after sample 
collection and therefore larger studies with a pre-specified primary objective of defining the association 
with outcome by plasma AR status could provide further supportive evidence for the role of AR CN as a 
biomarker in CRPC. For level one evidence to change clinical practice, our findings require confirmation 
in prospective trials where plasma AR CN defines treatment selection. 
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Legend to figures 
 
Figure 1. Association of plasma AR status and outcome in the Primary cohort. Overall and 
progression-free survival for AR copy number normal, gain and mutated (Mut, p.L702H or p.T878A) 
chemotherapy-naïve (A, C) and post-docetaxel (B, D) castration-resistant prostate cancer patients 
treated with enzalutamide or abiraterone. PSA declines by AR status, waterfall plots of PSA declines for 
AR copy number normal, gain and mutated (Mut, p.L702H or p.T878A) chemotherapy-naïve (E) and 
post-docetaxel (F) castration-resistant prostate cancer patients. Bars were clipped at maximum 100%. 
 
Figure 2. Association of plasma AR status and outcome in PREMIERE cohort. Biochemical 
progression-free survival (A), radiographic progression-free survival (B) and overall survival (C) for AR 
copy number normal versus AR gain patients. Waterfall plot (D) showing the magnitude of PSA decline 
by AR status. Bars were clipped at maximum 100%.  
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  Table 1. Baseline characteristics of the primary cohort by AR status 
 
 
Enzalutamide 
chemotherapy-naive 
(n=35) 
Abiraterone 
chemotherapy-naive* 
(n=38) 
Enzalutamide 
post-docetaxel 
(n=27) 
Abiraterone 
post-docetaxel 
(n=71) 
n (%) 
AR normal 
29 (83) 
AR gain 
6 (17) 
AR normal 
34 (89) 
AR gain 
4 (11) 
AR normal 
20 (74) 
AR gain 
7 (26) 
AR normal 
37 (52) 
AR gain 
26 (37) 
AR mutant 
8 (11) 
Age, years 
Median (range) 
73 
(63-91) 
71.5 
(63-81) 
75 
(56-87) 
75 
(66-86) 
78 
(59-87) 
81 
(65-85) 
75 
(41-82) 
73 
(41-91) 
77 
(63-86) 
Pretreatment PSA, mg/liter 
Median (range) 
28 
(2-1555) 
110 
(32-298) 
15 
(1-191) 
313 
(126-797) 
23 
(2-1899) 
252 
(11-893) 
56 
(1-3211) 
142 
(2-3150) 
144 
(1-803) 
Pretreatment LDH, U/liter 
Median (range) 
164 
(80-915) 
169 
(137-253) 
154 
(77-253) 
219 
(134-312) 
154 
(78-234) 
201 
(167-245) 
172 
(106-417) 
222 
(135-968) 
250 
(157-650) 
Pretreatment ALP, U/liter 
Median (range) 
76 
(44-531) 
65 
(55-188) 
92 
(51-426) 
175 
(102-255) 
90 
(55-531) 
241 
(87-890) 
93.5 
(61-934) 
96 
(36-1040) 
119 
(39-891) 
Previous cabazitaxel 
treatment, n (%)  
- - - - 2 (10) 1 (14) 0 (0) 3 (11) 1 (12.5) 
Sites of metastases, n (%), 
visceral metastases, n (%) 
≤ 5 bone metastases 
>5 bone metastases 
Lymph node, no bone 
metastases 
 
 
6 (21),0 (0) 
4 (14),0 (0) 
4 (14), 0 (0) 
 
 
1 (17), 0 (0) 
2 (33), 0 (0) 
0 (0), 0 (0) 
 
 
13 (38), 0 (0) 
14 (41), 2 (6) 
5 (15), 1 (3) 
 
 
1(25), 0 (0) 
3 (75), 0 (0) 
0 (0), 0 (0) 
 
 
5 (40), 0 (0) 
12 (60), 2 (10) 
1 (5), 0 (0) 
 
 
3 (43), 0 (0) 
4 (57), 1 (14) 
0 (0), 0 (0) 
 
 
12 (32), 3 (8) 
17 (46), 2 (5) 
6 (16), 1 (3) 
 
 
8 (31), 2 (8) 
17 (65), 4 (15) 
1 (4), 1 (4) 
 
 
3 (37.5), 1 (12.5) 
5 (62.5), 1 (12.5) 
0 (0), 0 (0) 
Pretreatment dsDNA 
concentration, ng 
Median (range) 
 
17 
(6-577) 
 
15 
(11-27) 
 
19 
(6-103) 
 
39 
(29-134) 
 
27 
(7-190) 
 
40 
(9-121) 
 
24 
(4-783) 
 
65 
(7-2566) 
 
32 
(11-550) 
Time of follow-up, months 
Median (range) 
27.8 (5.2-33.0) 18.5 (0.9-28.5) 26.1 (0.8-39.9) 44.5 (1.1-68.0) 
* No AR (p.L702H or p.T878A) mutation detected.    
        Abbreviations: ALP alkaline phosphatase; AR, Androgen receptor; dsDNA, double strand DNA; LDH, lactate dehydrogenase; n, number; NLR, neutrophil to lymphocyte ratio; PSA, prostate 
specific antigen.
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Table 2. Multivariable Cox Proportional Hazard Analysis of Predictors of Overall Survival (A) and 
Progression-free Survival (B) for Primary Cohort after stepwise backwards elimination 
 
A 
 
Overall Survival 
HR CI 95% p 
AR gain 
(yes versus no) 
4.26 2.76-6.55 < 0.001 
AR mutant 
(yes versus no) 
3.80 1.77-8.15    0.001 
Pretreatment dsDNA concentration 
(continuous variable) 
1.00 1.00-1.00  < 0.001 
 
 
B 
 
Progression-free Survival 
HR CI 95% p 
AR gain 
(yes versus no) 
2.22 1.48-3.34 < 0.001 
AR mutant 
(yes versus no) 
2.59 1.24-5.44 0.012 
ALP  
(>UNL versus ≤UNL) 
1.64 1.13-2.36 0.009 
Pretreatment dsDNA concentration 
(continuous variable) 
1.00 1.00-1.00 < 0.001 
Abbreviations. ALP alkaline phosphatase; AR, androgen receptor; HR, hazard ratio; CI, 
confidence interval; dsDNA, double-stranded DNA; UNL, upper normal limit. 
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Table 3. PREMIERE cohort. Baseline characteristics of patients according to AR status (A). 
Multivariable Cox proportional hazard analysis of predictors of PSA progression-free survival (B). 
 
  A 
 
 
PREMIERE 
(n=94) 
n (%) 
AR normal 
83 (88) 
AR gain 
11 (12) 
Age, years 
Median (range) 
77 
(57-95) 
80 
(60-88) 
PSA, mg/liter 
Median (range) 
24 
(3-4319) 
59 
(2-254) 
Prior bicalutamide at CRPC, n (%) 69 (83) 9 (82) 
Sites of metastases, n (%), visceral 
metastases, n (%) 
≤ 5 bone metastases 
>5 bone metastases 
Lymph node, no bone metastases 
 
 
57 (69), 10 (12) 
12 (15), 1 (1) 
12 (15), 2 (2) 
 
 
8 (73), 1 (9) 
1 (9), 0 (0) 
1 (9), 0  (0) 
dsDNA concentration, ng/mL 
Median (range) 
19.4 
 (0.5-134.7) 
23.1 
(4.4-1584.9) 
CTC detection, n (%) 
Yes 
No 
 
28 (34) 
55 (66) 
 
7 (64) 
4 (36) 
Time of follow-up, months 
Median (range) 
10.8 
(2.8-16.7) 
 
 
B 
AR gain 
 
sPFS rPFS 
HR CI 95% p HR CI 95% p 
AR gain  
(yes versus no) 
4.32 1.90-9.85 < 0.001 5.63 2.15-14.74 < 0.001 
Pretreatment dsDNA 
concentration 
(continuous variable) 
1.00 1.00-1.00  0.240 1.00 1.00-1.00   0.853 
CTC detection (AdnaTest®)  
(yes versus no) 
3.18 1.63-6.20  0.001 5.74 2.08-15.90   0.001 
Abbreviations. AR, androgen receptor; CI, confidence interval; CRPC, castration resistant prostate cancer; 
CTC, circulating tumor cell; dsDNA, double-stranded DNA; HR, hazard ratio; PSA, prostate specific antigen; 
rPFS, Radiographic Progression-free Survival; sPFS, Progression-Free Survival. 
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Appendix S1 
1. Eligibility Criteria of Primary cohort 
Inclusion Criteria 
1. Patients must have histologically-confirmed adenocarcinoma of prostate without neuroendocrine 
differentiation or small cell histology. 
2.  Patients have progressive disease despite “castration levels” of serum testosterone (<50 ng/dL) (≤1.73 
nmol/L), and ongoing LHRH analogue treatment or prior surgical castration. 
3.  Progression as defined by at least two of the following: a rise in PSA, worsening symptoms, or 
radiological progression, namely, progression in soft tissue lesions measured by computed tomography 
imaging according to the modified Response Evaluation Criteria in Solid Tumors (RECIST) or 
progression on bone scanning according to criteria adapted from the Prostate Cancer Working Group 
(PCWG2) criteria. 
4.   Patients have not received radiotherapy, chemotherapy, or immunotherapy at least 30 days prior to the 
treatment. 
5.    Male, aged ≥18 years. 
6.    Life expectancy of greater than three months. 
7.    Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2. 
8.    Able to swallow the study drug whole as a tablet. 
9.    Willing to use a method of birth control with adequate barrier protection. 
10.  Patients must have normal organ and marrow function as defined below: 
a.     leukocytes >3,000/mL 
b.     absolute neutrophil count >1,500/mL 
c.     platelets >100,000/mL 
d.     total bilirubin within normal institutional limits 
e.     AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal 
f.       creatinine within normal institutional limits 
11.  No evidence (within five years) of prior malignancies (except successfully treated basal cell or 
squamous cell carcinoma of the skin). 
12.  Participant is willing and able to give informed consent for participation in the study. 
 
Exclusion Criteria 
1.   Patients who have had previous therapy with abiraterone and/or enzalutamide. 
2.   Concurrent use of other anticancer agents or treatments, with the following exceptions: 
a.     LHRH agonists or antagonists 
b.     denosumab or bisphosphonate (e.g., zoledronic acid). 
3.  Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic 
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social 
situations that would limit compliance with study requirements. 
4.  History of seizures or any disease that could predispose to seizure, including history of lost of 
consciousness or transient stroke in the last 12 months before inclusion (day 1). 
5.    Have a history of gastrointestinal disorders that may interfere with the absorption of the study agents. 
6.    Have a pre-existing condition that warrants long-term corticosteroid use in excess of study dose. 
7.    Have known allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone, enzalutamide, 
or their excipients. 
8.   Other primary tumor (other than CRPC) including hematological malignancy present within the last five 
years (except non-melanoma skin cancer or low-grade superficial bladder cancer). 
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2. Eligibility Criteria of PREMIERE cohort 
Inclusion criteria. 
1. Age ≥18 years old. 
2. Histologically or cytologically confirmed of prostate adenocarcinoma without neuroendocrine 
differentiation or small cell characteristics. 
3. Ongoing androgen deprivation with GnRH analog or bilateral orchiectomy. 
4. Testosterone serum levels ≤1.73 nmol/L or 50 ng/dL at the screening visit. 
5. Patients receiving bisfosfonate therapy must have been on stable doses for at least four weeks 
before study entry. 
6. Progressive disease at study entry, defined by one or more of the three following criteria while the 
patient was on androgen deprivation therapy: 
a. PSA progression defined by a minimum of two rising PSA values with an interval of ≥one 
week between each determination. Patients that have received anti-androgen must be in 
progression upon anti-androgen withdrawal at least four weeks for flutamide and six weeks 
since the last dose of bicalutamide or nilutamide. PSA value should be ≥2 µg/L (2 ng/mL). 
b. Progression in soft tissue according to RECIST 1.1 
c. Bone progression defined by the PCWG2 criteria, at least two new more lesions in the bone 
scan. 
7. Metastatic disease documented by bone lesions in bone scan or by measurable soft tissue lesions 
by CT or MRI. Patients whose disease was limited to lymph nodes were required to have a lesion 
with a minor diameter of 2.5 cm. 
8. No prior cytotoxic chemotherapy for prostate cancer. 
9. Patients without previous abiraterone acetate treatment. 
10. Asymptomatic or minimally symptomatic disease from prostate cancer (i.e., the score on Brief Pain 
Inventory question Short form question #3 must be <4). 
11. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 
12. Estimated life expectancy of ≥ six months. 
13. Patient able to swallow the study drug and to follow-up the study requirements. 
14. Informed consent for the biomarker study: TMPRSS2-ETS rearrangement and the obtained 
samples. 
 
Exclusion criteria. 
1. Comorbidity, infection or severe concurrent disease, in the judgment of the investigator, that makes 
the patient not suitable for inclusion in the study. 
2. Known or suspicion of brain or leptomeningeal disease. 
3. History of another malignancy within the previous 5 years other than cured non-melanoma skin 
cancer. 
4. Hematological count at screening selection: 
a. Absolute neutrophil count <1,500/µL 
b. Platelet count <100,000/µL 
c. Haemoglobin <5.6 mmol/L (9 g/dL) 
5. Liver function at the screening visit: total bilirubin, aminotransferase (ALT) or aspartate 
aminotransferase (AST) >2.5 times upper normal limit. 
6. Renal function at the screening visit: creatinine >177 µmol/L.  
7. Albumin value <30 g/L (3 g/dL) at the screening visit. 
8. History of seizures or any disease that could predispose to seizure, including history of lost of 
consciousness or transient stroke in the last 12 months before inclusion (day 1). 
9. Clinically significant cardiovascular disease, including: 
a. Myocardial infarction within six months 
b. Uncontrolled angina within three months 
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c. Congestive heart failure New York Heart Association (NYHA) class III or IV or history of congestive 
heart failure class III or IV in the past, unless a screening echocardiogram or multi-gated acquisition 
scan performed within three months results in a left ventricular ejection fraction ≥45%. 
d. History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia) 
e. Heart block (Mobitz II or III without a permanent pace-maker in place. 
f. Hypotension at the screening visit, as indicated by systolic blood pressure <86 mmHg) 
g. Bradycardia as indicate by a heart rate of <50 beats per minute on the screening ECG. 
h. Uncontrolled hypertension as indicated by systolic blood pressure >170 or diastolic blood pressure 
>105 rpm at the screening visit. 
10. Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within 
three months). 
11. Major surgery within last four months of inclusion. 
12. Use of opioids for pain within four weeks before screening visit. 
13. Use of radiotherapy for the treatment of the primary tumor within three weeks before treatment. 
14. Use of radiotherapy for the treatment of metastasis within two months before study entry. 
15. Use of radium-223 or other radionuclides for the treatment of bone disseminated disease. 
16. Treatment with flutamide within four weeks of enrollment. 
17. Treatment with bicalutamide or nilutamide within six weeks before enrollment in the study. 
18. Treatment with 5-α reductase (finasteride, dutasteride), estrogens or ciproterone acetate within 
four weeks of enrollment. 
19. Treatment with biological therapy for prostate cancer (other than bone targeted agents and GnRH 
analogues) or other drugs with antitumoral activity in the four weeks before study entry. 
20. History of prostate cancer progression on ketoconazole. 
21. Previous use, or participation in a clinical trial, of an investigational drug that blocks androgen 
synthesis (e.g., abiraterone, TAK-100, TAC 683, TAK-448) or target the androgen receptor (e.g., 
ARN507, BMS641988). 
22. Participation in a clinical trial including enzalutamide. 
23. Use of an investigational drug in the four weeks of enrollment. 
24. Use of herbal products that may have hormonal anti-cancer activity or that modify PSA levels, 
systemic steroids at a dose higher than the equivalent of 10 mg of prednisone within four weeks of 
enrollment. 
25. Hereditary fructose intolerance. 
Any condition or reason that in the opinion of the investigator interferes with the ability of the 
patient to participate in the trial, which places the patient at undue risk, or complicates the 
interpretation of safety data. 
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Appendix S2. Detection of AR aberrations by digital droplet PCR in plasma samples 
 
Circulating DNA was extracted from one to two ml of plasma with the QIAamp Circulating Nucleic Acid Kit 
(Qiagen). Total extracted plasma DNA was quantified with the Quant-iT high sensitivity PicoGreen double-
stranded DNA Assay Kit (Invitrogen). DdPCR was performed on a QX200 ddPCR system (Bio-Rad). Copy 
number (CN) assays were performed for AR (Hs04121925_cn, FAM) and centromeric chromosome X gene 
ZXDB (Hs02220689_cn, FAM, Life Technologies) with NSUN3 (dHsaCP2506682, HEX, Bio-Rad), ElF2C1 
(dHsaCP1000002, HEX, Bio-Rad), and AP3B1 (dHsaCP1000001, HEX, Bio-Rad) as reference genes. We 
developed multiplex assays by varying the concentration of the fluorescent probes to differentiate droplets 
positive for respective genes on the basis of fluorescence intensity [1-3]. 
Rare mutation detection assays were performed for the AR mutations 2105T>A (p.L702H), 2632A>G 
(p.T878A), and 2629T>C (p.F876L) using a custom-made single nucleotide polymorphism (SNP) 
genotyping assay (Life Technologies), the SNP genotyping assay rs137852581 (Life Technologies), and 
the SNP genotyping assay rs137852578 (Life Technologies), respectively. 
PCR reactions were prepared with 1-2 ng DNA, 10ul 2xSupermix and a total volume of primer probe 
assays of 2ul in a total volume of 20ul. PCR reactions were partitioned into ~20,000 droplets per sample 
with an Automated Droplet generator (Bio-Rad). Emulsified PCR reactions were run on a Mastercycler 
Nexus GSX1 (Eppendorf). For mutation assays, ddPCR conditions were optimized with a temperature 
gradient to identify the optimal annealing/extension temperature using wild-type DNA spiked with a 
synthetic oligonucleotide containing the mutation of interest. We selected the optimal temperature for 
incubation on the Mastercycler Nexus GSX1. Samples were incubated at 99°C for 10 min followed by 40 
cycles of 95°C for 15 sec, 60°C for 60 sec, followed by 10 min incubation at 98°C for the AR copy number 
multiplex assay. For AR mutation detection, samples were incubated at 99°C for 10 min followed by 40 
cycles of 95°C for 15 sec, 56-61°C for 60 sec, followed by 10 min incubation at 98°C.  
Samples were read on a Bio-Rad QX200 droplet reader using QuantaSoft v1.3.2.0 software for AR CN 
analysis and mutation detection. At least two negative control wells with no DNA were included in every 
run. An oligo carrying the mutation of interest was used as a positive control for mutation assays. In 
addition, two wells with DNA from a germ line sample, characterized by the complete absence of mutation 
and normal AR CN status, were also included. Positive and negative clusters were gated using the FAM 
and VIC/HEX thresholds based on the amplitude of positive and negative controls that were ran 
concomitantly with each assay. Poisson distribution was used to estimate the average number of copies 
per reaction microliters. CN ratios of AR and reference genes and mutant vs wild-type were calculated for 
each sample to determine AR CN and the mutation allele fraction respectively as described previously [4].  
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Appendix S3. Statistical analysis 
 
Using NGS we previously used AR amplicon variance in healthy volunteer plasma to set a cut-off of 1.91 
for calling a patient CN gain. We do not observe variance with ddPCR and could therefore theoretically 
choose any cut-off >1. We performed a systematic search over all observed values of AR CN to identify the 
AR CN, which optimally splits the patients into two groups who have different prognosis of overall survival 
as we had hypothesized that AR gained patients have higher hazard rates than AR normal patients. AR 
mutant patients were excluded for this research. We used log-likelihood as correlative measure in a 
multivariable Cox proportional hazard model which included AR CN and serum lactate dehydrogenase as 
the second variable and was stratified by chemotherapy status of the patients It has been shown that 
multivariable approach increases the accuracy of the cutpoint [5]. We used bootstrapping with replacement 
technique and iterated the search for the optimal cutpoint 30,000 times to estimate the measures of 
dispersion of the cutpoint. The search for cutpoint and the bootstrapping were performed using an in-house 
developed R script (supplementary Figure S2, available at Annals of Oncology online).  
The association of AR status with progression-free survival (PFS) and overall survival (OS) was evaluated 
using univariable Cox regression. Survivor function of Time-to-event outcomes were also estimated using 
the Kaplan-Meier method. Differences between survivor functions of patients with AR CN gain vs AR CN 
normal (and AR mutant vs AR no mutant in docetaxel-treated patient group) were evaluated using the log-
rank test. The association of AR status with time-to event outcomes was evaluated and hazard ratios (HRs) 
estimated from univariable and multivariable Cox proportional hazards regression methods (Figure 1A-C 
and Figure 2A-C).   
Best PSA responses were depicted using standard waterfall plots; odds ratios (ORs) and the corresponding 
95% confidence interval (CI) of PSA response were determined using a 2x2 contingency table and the 
Woolf logit method. Statistical significance was determined using Fisher’s exact test (Figure 1E-F and 
Figure 2D).  
The pre-treatment predictors evaluated for the multivariable Cox proportional hazards models included AR 
CN (gain vs normal), AR mutant (yes vs no), lactate dehydrogenase levels [>upper normal limit (UNL) vs 
≤UNL], presence of liver metastases (yes vs no), presence of bone metastases (≤5 vs >5), neutrophil-to-
limphocyte ratio (>3 vs <3), alkaline phosphatase levels (>UNL vs ≤UNL), hemoglobin levels (≥UNL vs 
<UNL), albumin levels (>UNL vs ≤UNL), previous chemotherapy (yes vs no), dsDNA concentration 
(continuous variable), PSA levels (continuous variable), and patient age (continuous variable) 
(supplementary Table S4 and Table S5B, available at Annals of Oncology online). The final multivariable 
analyses were assessed using a proportional hazard model after stepwise backwards elimination by Akaike 
information criterion (Table 2).  
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Supplementary Figures 
 
A 
 
B 
 
 
 
 
Figure S1. Evaluation of ddPCR copy number (CN) and mutation assay performance. Bland-Altman 
plot showing agreement of ddPCR and NGS AR copy number assessment, low tumor content samples had 
a tumor content fraction below 0.075 (A). Bland-Altman plot showing agreement of ddPCR and NGS AR 
mutation frequencies (B). 
 
 
A 
Page 35 of 64 Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
8 
 
 
B 
 
 
Figure S2. Selection of cut-off for AR CN gain by ddPCR. Range of AR CN across primary cohort (A), 
Cut-off analysis with maximum log-likelihood as the correlative statistic of the multivariable Cox proportional 
hazard model and boot-strapping with 30,000 iterations to provide the cut-off point dispersion (B). 
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Supplementary Tables 
 
Table S1. Samples analysed by both NGS and ddPCR 
 
  Pretreatment (n) Progression (n) 
NGS data included in 
previously published 
cohort [6] 
Chemotherapy-naive 8 1 
Post-docetaxel 58 19 
NGS data not in 
previously published 
cohort 
Chemotherapy-naive 53 22 
Post-docetaxel 0 0 
 T tal 119 42 
Abbreviations. ddPCR, droplet digital PCR; n, number; NGS, next generation sequencing. 
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Table S2. Agreement of AR CN gain call by ddPCR vs NGS 
 
Chemotherapy-naive 
Cut off 2.01 
AR Normal NGS AR Gain NGS NGS TC <0.075 
AR Normal ddPCR 57 3 12 
AR Gain ddPCR 1 10 0 
Post-docetaxel 
Cut off 2.01 
AR Normal NGS AR Gain NGS NGS TC<0.075 
AR Normal ddPCR 37 1 12 
AR Gain ddPCR 1 23 3 
 Abbreviations. AR, androgen receptor; ddPCR, digital droplet PCR; NGS, next generation sequencing; TC,  
 tumor content. 
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Table S3. Univariate analysis in the primary cohort 
 
 
 Overall Survival Progression-free Survival 
 HR CI 95% p HR CI 95% p 
AR gain  
(yes vs no) 
4.07 2.68-6.20 < 0.001 2.33 1.61-3.36 < 0.001 
AR mutant 
(yes vs no) 
4.81 2.02-11.44 < 0.001 2.86 1.24-6.59 0.014 
Previous chemotherapy  
(yes vs no) 
2.38 1.51-3.75 < 0.001 1.92 1.36-2.71 < 0.001 
Pretreatment dsDNA concentration 
(continuous variable) 
1.00 1.00-1.00 < 0.001 1.00 1.00-1.00 < 0.001 
Pretreatment LDH  
(>UNL vs ≤UNL) 
2.21 1.50-3.24 < 0.001 1.91 1.35-2.68 < 0.001 
Liver metastases  
(yes vs no) 
2.61 1.35-5.02 0.004 1.61 0.84-3.08 0.147 
Bone metastases  
(>5 vs ≤5) 
1.68 1.15-2.46 0.007 1.49 1.07-2.07 0.017 
NLR  
(>3 vs <3) 
1.67 1.13-2.46 0.010 1.34 0.96-1.87 0.080 
ALP  
(>UNL vs ≤UNL) 
2.00 1.36-2.93 0.010 2.09 1.48-2.94 < 0.001 
Hb 
(<UNL vs ≥UNL) 
1.80 1.20-2.69 0.004 1.50 1.03-2.18 0.031 
Albumin  
(<UNL vs ≥UNL) 
1.41 0.92-2.15 0.110 1.32 0.93-1.87 0.120 
PSA 
(continuous variable) 
1.00 1.00-1.00 0.009 1.00 1.00-1.00 0.002 
Age 
(continuous variable) 
0.98 0.95-1.00 0.054 0.98 0.96-1.00 0.104 
Abbreviations. ALP alkaline phosphatase; AR, androgen receptor; CI, confidence interval; dsDNA, double-stranded DNA; Hb, 
hemoglobin; HR, hazard ratio; LDH, lactate dehydrogenase; NLR, neutrophil to lymphocyte ratio; PSA, prostate specific antigen; UNL, 
upper normal limit.  
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Table S4. Multivariable Cox Proportional Hazard Analysis of predictors of overall survival and 
progression-free survival for primary cohort 
 
 
Overall Survival Progression-free Survival 
HR CI 95% p HR CI 95% p 
AR gain 
(yes vs no) 
3.81 2.37-6.12 < 0.001 2.05 1.31-3.19 0.002 
AR mutant 
(yes vs no) 
3.12 1.32-7.40 0.010 2.23 0.98-5.08 0.056 
Previous chemotherapy  
(yes vs no) 
1.27 0.72-2.23 0.407 1.39 0.89-2.17 0.147 
Pretreatment dsDNA concentration 
(continuous variable) 
1.00 1.00-1.00 0.010 1.00 1.00-1.00 < 0.001 
Pretreatment LDH 
(>UNL vs ≤UNL) 
1.31 0.81-2.11 0.273 1.21 0.79-1.87 0.379 
Liver metastases 
(yes vs no) 
1.49 0.69-3.21 0.312 0.76 0.34-1.68 0.493 
Bone metastases 
(>5 vs ≤5) 
1.35 0.87-2.11 0.184 1.22 0.83-1.79 0.304 
NLR 
(>3 vs <3) 
1.37 0.89-2.11 0.156 1.06 0.73-1.54 0.759 
ALP 
(>UNL vs ≤UNL) 
1.32 0.85-2.05 0.222 1.43 0.95-2.14 0.086 
Hb 
(<UNL vs ≥UNL) 
0.91 0.55-1.50 0.705 0.79 0.49-1.26 0.314 
Albumin 
(<UNL vs ≥UNL) 
1.01 0.61-1.65 0.980 1.07 0.71-1.62 0.730 
PSA 
(continuous variable) 
1.00 1.00-1.00 0.458 1.00 1.00-1.00 0.766 
Age 
(continuous variable) 
0.99 0.96-1.02 0.386 0.99 0.96-1.01 0.309 
Abbreviations. ALP alkaline phosphatase; AR, androgen receptor; CI, confidence interval; dsDNA, double-stranded DNA; Hb, 
hemoglobin; HR, hazard ratio; LDH, lactate dehydrogenase; NLR, neutrophil to lymphocyte ratio; PSA, prostate specific antigen; UNL, 
upper normal limit.  
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Table S5. Univariate analysis in PREMIERE. Biochemical PFS (A) and radiographic PFS (B)  
 
A 
 
 sPFS 
 HR CI 95% p 
AR gain  
(yes vs no) 
4.33 1.94-9.68 < 0.001 
Pretreatment dsDNA concentration 
(continuous variable) 
1.00 1.00-1.00 0.779 
CTCs (AdnaTest®)  
(detected vs not detected) 
3.40 1.76-6.56 < 0.001 
 
 
 
B 
 rPFS 
 HR CI 95% p 
AR gain  
(yes vs no) 
8.06 3.26-19.93 < 0.001 
Pretreatment dsDNA concentration 
(continuous variable) 
1.00 1.00-1.00 0.012 
CTCs (AdnaTest®)  
(detected vs not detected) 
7.09 2.61-19.25 < 0.001 
 
Abbreviations. AR, androgen receptor; CI, confidence interval; CTC, circulating tumor cell; dsDNA,  
double-stranded DNA; HR, hazard ratio; sPFS, biochemical progression-free survival; rPFS,  
radiographic progression-free survival. 
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ABSTRACT 
BACKGROUND  
There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistance 
prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) status measurement in 
plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. 
 
METHODS 
We optimised ddPCR assays for AR copy number and mutations and retrospectively analysed plasma 
DNA from patients recruited to one of three biomarker protocols with prospectively-collected clinical 
data. We evaluated associations between plasma AR and overall survival (OS) survival (OS) and  
survival (OS) and progression-free survival (PFS) in 73 chemotherapy-naïve and and 98 98 post-
docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary cohort) and 94 
chemotherapy-naïve patients treated with enzalutamide (Secondary cohort; PREMIERE trial).treated 
with enzalutamide or abiraterone. 
 
RESULTS  
In the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-
docetaxel patients and associated with worse OS (Hazard Ratio (HR), 3.98; 95%CI, 1.74-9.10; p<0.001 
and HR, 3.81; 95%CI, 2.28-6.37; p<0.001 respectively), PFS (HR, 2.18; 95%CI, 1.08-4.39; p=0.03, and 
HR, 1.95; 95%CI, 1.23-3.11; p=0.01 respectively) and rate of PSA decline ≥50% (Odds ratio (OR), 4.7; 
95%CI, 1.17-19.17; p=0.035 and OR, 5.0; 95% CI, 1.70-14.91; p=0.003 respectively). AR mutations 
(2105T>A (p.L702H) and 2632A>G (p.T878A)) were observed in eight (11%) post-docetaxel but no 
chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 
95%CI, 1.47-not reached; p=0.004). There was no interaction between AR and docetaxel status 
(p=0.83 for OS, p=0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse 
sPFS (HR, 4.33; 95%CI, 1.94-9.68; p<0.001), rPFS (HR, 8.06; 95% CI, 3.26-19.93; p<0.001) and OS 
(HR, 11.08; 95%CI, 2.16-56.95; p=0.004). Plasma AR was an independent predictor of outcome on 
multivariate analyses in both cohorts.  
 
CONCLUSION 
Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or 
abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required. 
 
Clinical Trial number:NCT02288936 (PREMIERE trial) 
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Key words: castration-resistant prostate cancer, androgen receptor, plasma DNA, enzalutamide, 
abiraterone, biomarker 
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INTRODUCTION 
Inhibition of androgen receptor (AR) signaling with abiraterone or enzalutamide is now standard 
treatment at emergence of castration-resistant prostate cancer (CRPC). However, the duration of 
response is variable and overall survival (OS) in unselected patients is modest despite some patients 
having responses that last several years [1, 2]. There is therefore an urgent need to develop biomarker 
strategies to a priori identify CRPC patients who will derive minimal benefit from AR targeting and offer 
them an alternative treatment paradigm. Testing for plasma Epidermal Growth Factor Receptor (EGFR) 
mutations has FDA clearance for selection of mutant lung cancer patients for EGFR tyrosine kinase 
inhibitors and studies of plasma DNA in multiple indications have suggested clinical utility for monitoring 
of mutations or copy number (CN) gain [3-6]. 
 
Next-generation sequencing (NGS) and PCR-based studies have identified associations between AR 
CN gain detected in plasma and worse outcome with abiraterone or enzalutamide, in predominantly 
post-docetaxel CRPC cohorts [7-12]. AR gene aberrations are rare prior to hormone therapy but occur 
in metastases harvested at rapid warm autopsy from up to 60% of patients [13]. Using NGS on 
sequential plasma samples, we have identified two AR point mutations (2105T>A (p.L702H) and 
2632A>G (p.T878A)) as associating with resistance to abiraterone, shown previously to be activated by 
prednisone or progesterone respectively [7, 8, 14, 15]. For enzalutamide, the 2629T>C (p.F877L) point 
mutation has been reported as a resistance mechanism [16, 17] although a recent study suggested it is 
very uncommon [12]. Following a well-described roadmap for implementation of a biomarker test into 
routine clinical practice [18], we aimed to optimize a droplet digital PCR (ddPCR) assay that is fit for 
purpose and can be widely implemented on plasma DNA in clinical laboratories. We sought to define 
AR CN and in a separate reaction, AR mutation status: 2105T>A and 2632A>G in patients considered 
for abiraterone and 2629T>C for patients treated with enzalutamide. We then aimed to obtain stage 
one biomarker clinical qualification for associations with clinical outcome on enzalutamide or 
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abiraterone in chemotherapy-naïve and post-docetaxel CRPC patients treated in one of three 
biomarker protocols.   
 
MATERIAL AND METHODS 
Study design  
This was a multi-institution analysis of plasma samples collected prospectively in studies with the 
primary aim of biomarker evaluation. The objectives were defined after sample collection but prior to 
plasma analysis. Our first objective was to determine the correlation between ddPCR testing for plasma 
AR and an orthogonal approach, next-generation sequencing (NGS), in samples collected prior to 
starting treatment and after disease progression. Our second objective was to evaluate associations 
between pre-treatment plasma AR and clinical outcome in a primary cohort, representative of both pre- 
and post-docetaxel patients, and test for interactions with prior chemotherapy exposure. As no trial to 
date has randomised patients between first-line enzalutamide or abiraterone and taxanes, we 
combined data from four cohorts of men recruited to two biomarker protocols and defined by treatment 
with enzalutamide or abiraterone and prior chemotherapy status. Our third objective was to test our 
ddPCR assay in a second cohort of chemotherapy-naïve men treated with enzalutamide in the 
PREMIERE trial.  
 
Participants 
The primary cohort included patients participating in one of two protocols separately approved by the 
Institutional Review Board of the Royal Marsden (RM), London, UK (REC 04/Q0801/6), and Istituto 
Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy (REC 2192/2013). 
Docetaxel in this cohort was only used in the CRPC setting. The second cohort was the PREMIERE 
trial (EudraCT: 2014-003192-28, NCT02288936) that was sponsored and conducted by the Spanish 
Genito-Urinary oncology Group (SOGUG). The trial was approved by the independent review board at 
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each participating site. This trial was designed to analyse the predictive value of the gene fusion 
TMPRSS2-ETS in response to enzalutamide in patients with prostate cancer. Exploratory end-points 
included circulating cell-free DNA and circulating tumor cell (CTC) analysis. Data emerging after the 
trial was designed and initiated [7, 19, 20] led the PREMIERE Trial Management Group to prioritize two 
alternative biomarkers for evaluation, namely AR-V7 detected in CTCs as described previously [19] and 
plasma AR. TMPRSS2-ETS analyses are on-going and will be reported elsewhere. Preliminary AR-V7 
data was presented in abstract form at the ESMO 2016 Annual Meeting [21] and will be published 
elsewhere. These analyses were based on the first censor cut-off, date May 2016. A second data 
analysis is planned at a predefined time-point when enough events have occurred to address the 
primary endpoint.  
 
In both cohorts, patients were required to have histologically-confirmed prostate adenocarcinoma 
without neuroendocrine differentiation, progressive disease despite “castration levels” of serum 
testosterone (<50 ng/dL), on-going LHRH analogue treatment or prior surgical castration and no prior 
treatment with enzalutamide or abiraterone. Additional selection criteria by cohort are specified in the 
Supplementary Appendix S1, available at Annals of Oncology online. The choice of therapy in the 
primary cohort was at the discretion of the treating physician, either enzalutamide 160mg once a day or 
abiraterone 1g once a day and prednisone 5mg twice daily. In the PREMIERE trial, all patients received 
enzalutamide 160mg once a day. Treatment in both cohorts was administered continuously until 
evidence of progression disease or unacceptable toxicity. The studies were conducted in accordance 
with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International 
Conference of Harmonization. Written informed consent was obtained from all patients. 
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Procedures 
Peripheral blood samples were collected within 30 days of treatment initiation and plasma aliquots 
stored at -80°C. ddPCR assays were performed as described in detail in Supplementary Appendix S2, 
available at Annals of Oncology online. For each individual sample AR CN was estimated using each of 
the reference genes NSUN3, ElF2C1, and AP3B1 and using ZXDB at Xp11.21 as a control gene to 
determine X chromosome CN. AR mutation detection assays were performed for the AR mutations 
2105T>A (p.L702H), 2632A>G (p.T878A), and 2629T>C (p.F877L) with a limit of detection of 1-2% 
using an input of 2 to 4 ng of DNA. For NGS on plasma and patient-matched germline DNA, we used a 
customized AmpliSeq targeted gene panel including AR, sequenced on an Ion Torrent Personal 
Genome Machine or Proton as described previously [7, 8]. Computational analysis estimating the 
plasma DNA tumor content, AR CN quantitation and point mutation detection (with a sensitivity of 98-
99% depending on position and coverage) was performed as previously [8]. 
 
Serum prostate specific antigen (PSA) was assessed within one week of starting treatment and monthly 
thereafter. Radiographic disease was evaluated with the use of computed tomography and bone scan 
at the time of screening and every 12 weeks on treatment. In the primary cohort, serum lactate 
dehydrogenase (LDH) and alkaline phosphatase (ALP) were also measured within one week of starting 
treatment. In PREMIERE, CTCs were evaluated pre-treatment using the AdnaTest for Prostate Cancer 
(Qiagen GmbH, Germany) as described previously [21].  
 
Outcomes 
For the primary cohort, the primary endpoint was OS. The secondary endpoints were progression-free 
survival (PFS) (biochemical and/or radiographic and/or clinical) and PSA response. For PREMIERE, 
the primary endpoint was PSA-PFS (sPFS). Secondary endpoints included radiographic-PFS (rPFS), 
OS and PSA response. OS was calculated from initiation of therapy to death from any cause. Patients 
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still alive at time of last follow-up were censored. PFS was calculated from the first day of enzalutamide 
or abiraterone therapy to the date of progression disease or death. Radiographic progression was 
defined using Response Evaluation Criteria in Solid Tumors version 1.1. PSA decline was evaluated 
according to Prostate Cancer Working Group (PCWG2) guidelines [22].  
 
Statistical analyses 
An R script [23] was developed to identify the optimal AR CN cut-point that associated with OS in the 
primary cohort, using maximum log-likelihood as correlative statistics in a multivariable Cox regression 
model by an approach described previously (Supplementary Appendix S3, available at Annals of 
Oncology online) [24]. The process was boot-strapped with 30,000 iterations to provide the measures 
of dispersion. Remaining analyses were conducted using Stata/MP 13.1 for Windows. Qualitative 
variables were compared using the Fisher’s exact test. Time-to-event outcomes were evaluated using 
Kaplan-Meier survivor estimates, log-rank test and univariate and multivariable Cox-proportional 
hazards models. Selected clinically relevant baseline factors previously associated with prognosis were 
assessed for significant association with OS and PFS using an univariate Cox regression model. A 
multivariate Cox regression model was performed with a stepwise procedure to identify the prognostic 
factors for OS and PFS with a significance level of 0.05 for entry into the model. All tests were two-
sided and an α-error of 5% was considered as significant (Supplementary Appendix S3, available at 
Annals of Oncology online). 
An R script [23] was developed to identify the optimal AR CN cut-point that associated with OS in the 
primary cohort, using maximum log-likelihood as correlative statistics in a multivariable Cox regression 
model by an approach described previously (Supplementary Appendix S3, available at Annals of 
Oncology online) [24]. The process was bootstrapped with 30,000 iterations to provide the measures of 
dispersion. Remaining analyses were conducted using Stata/MP 13.1 for Windows. Time-to-event 
outcomes were evaluated using Kaplan-Meier survivor estimates, log-rank test and univariate and 
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multivariable Cox-proportional hazards models. The association of a selected set of clinically relevant 
baseline factors (previously showed to be associated with prognosis [25, 26] with OS and PFS was 
examined using a univariate Cox regression model. A multivariate Cox regression model was then 
performed with a stepwise procedure to identify the prognostic factors for OS and PFS with a 
significance level of <0.05 for entry into the model. All tests were two-sided and an α-error of 5% was 
considered as significant. Odds ratios of PSA response were determined using a 2x2 contingency table 
and significant differences using Fisher’s exact test. (Supplementary Appendix S3, available at Annals 
of Oncology online).  
 
RESULTS 
Clinical Characteristics of the Primary Cohort 
In the primary cohort, we had 171 men who started treatment with enzalutamide or abiraterone 
between Jan 31, 2011 and June 9, 2016, 73 prior to docetaxel and 98 after. All had received 
bicalutamide. Patient and treatment characteristics at the time of sample collection are detailed in Table 
1.  
 
Analytic Testing of Multiplex Droplet Digital PCR for Determination of Plasma AR Status 
We used an optimized multiplex AR CN ddPCR assay on 2-4ng DNA from all pre-treatment samples 
and an additional 42 samples collected after disease progression. On a further 2-4ng DNA, we tested 
for AR mutations. From patients in the primary cohort with ddPCR data, we had NGS data available 
from our previous publication [8] for 86 samples and we performed NGS on an additional 75 (samples 
described in Supplementary Table S1, available at Annals of Oncology online). We observed a strong 
agreement between NGS and ddPCR for CN quantitation (n=161, Bland-Altman test: mean difference, 
-0.02, 95% CI Limits of agreement, -2.45 to 2.41) (Supplementary Figure S1A and Table S2, available 
at Annals of Oncology online). Estimation of AR mutation allelic frequency by ddPCR also displayed 
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strong agreement with NGS (n=60, Bland-Altman test: mean difference -0.001, 95% CI limits of 
agreement, -0.015 to 0.016) with no cases of mutations detected by one approach but not the other 
(Supplementary Figure S1B, available at Annals of Oncology online).  
 
Plasma AR status in the Primary Cohort 
In our primary cohort, eight post-docetaxel (but no chemotherapy-naïve) abiraterone patients were AR 
point mutation positive prior to treatment (Table 1). We planned to analyse these separately for 
associations with outcome. All four patients with a 2105T>A (p.L702H) mutation had received at least 
six months of treatment with prednisone. We did not detect a 2629T>C (p.F877L) AR point mutation 
prior to treatment or in an additional 26 samples collected after progression on enzalutamide. Using 
maximum likelihood ratio as correlative statistics combined with boot-strapping, we identified an AR CN 
cut-point of 2.01 (interquartile range (IQR), 1.82-2.77 copies) for splitting patients into two distinct 
prognostic groups (Supplementary Figure S2, available at Annals of Oncology online). Use of this cut-
off was also supported by 95.5% concordance between NGS and ddPCR for classifying AR CN status 
(Supplementary Table S2, available at Annals of Oncology online). Overall, 10 (14%) chemotherapy-
naïve and 33 (34%) docetaxel-treated patients had AR gain (Table 1). 
  
Plasma AR Associates with Worse Outcome in the Primary Cohort 
There was a significant association for AR gain and OS in both chemotherapy-naïve (median, 12.40 
months versus not reached; HR, 3.98; 95% CI, 1.74-9.10; p < 0.001) (Figure 1A), and post-docetaxel 
patients (median, 9.51 versus 21.80 months; HR, 3.81; 95% CI, 2.28-6.37; p < 0.001) (Figure 1B). For 
AR mutants in abiraterone-treated, post-docetaxel patients, a significant association with worse survival 
was also seen (median 4.06 months; HR, 3.26; 95% CI, 1.47-not reached; p = 0.004) (Figure 1B). We 
also observed a significant association between PFS and AR gain for chemotherapy-naïve patients 
treated with enzalutamide or abiraterone (median, 7.30 versus 9.20 months; HR, 2.18; 95% CI, 1.08-
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4.39; p = 0.03) (Figure 1C) and for post-docetaxel patients (median, 5.00 versus 7.36 months; HR, 
1.95; 95% CI, 1.23-3.11; p = 0.01) (Figure 1D). A trend was seen for AR mutants to have worse PFS 
(median 4.10 months; HR, 2.10; 95% CI, 0.98-4.51; p = 0.057) (Figure 1D). Interactions between AR 
CN and treatment (abiraterone versus enzalutamide) (p = 0.41 for OS and p = 0.11 for PFS) or 
chemotherapy status (p = 0.83 for OS, p = 0.99 for PFS) examined in the Cox models were not 
significant. We also evaluated the association of AR status with the rate of PSA decline in the 
chemotherapy-naïve and post-docetaxel groups. Chemotherapy-naïve patients with AR gain were 4.7 
times less likely to have a ≥50% decline in PSA (95% CI, 1.17-19.17; p = 0.035) (Figure 1E). Plasma 
AR gain chemotherapy-treated patients were 5.0 times less likely to have a ≥50% decline in PSA (95% 
CI, 1.70-14.91; p = 0.003) (Figure 1F). For the eight AR mutant patients, a trend for a lower rate of 
≥50% PSA decline was seen (odds ratio (OR), 6.3; 95% CI, 0.72-54.59; p = 0.12) (Figure 1F). 
  
Plasma AR Independently Associates with Worse Outcome on Multivariate Analysis in the 
Primary Cohort.  
In our pre-specifiedPlasma AR status and 11 baseline characteristics previously shown to be clinically 
relevant [25,26] andwere evaluated by both univariate and multivariate analyses on the whole primary 
cohort. Pplasma AR gain or mutant were most significantly associated with OS or PFS  univariate and 
complete multivariate analyses multivariate analysis (Supplementary Table S3 and Table S4 available 
at Annals of Oncology online). and S4, available at Annals of Oncology online) We then performedand 
multivariate analysis withafter stepwise backwards elimination and the sole variables that remained 
significant wereincluding plasma AR status (HR, 4.1026; 95% CI, 2.676-6.355; p < 0.001, and HR, 
4.023.80; 95% CI, 1.877-8.66; pp < 0.001 = 0.011, for AR CN and AR mutant, respectively, Table 2A) 
and total plasma DNA concentration for OS and plasma AR status (HR, 2.06; 95% CI, 1.36-3.1248-
3.34; p = 0.001, and HR, 2.2059; 95% CI, 1.0324-4.695.44; p = 0.04112, for AR CN and AR mutant, 
respectively), total plasma DNA concentration and ALP levels for PFS (Table 2B). serum LDH and 
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chemotherapy status (univariate analyses included in Supplementary Table S3, available at Annals of 
Oncology online), AR status was independently associated with the primary endpoint of OS (HR, 
4.263.77; 95% CI, 2.7642-6.555.88; P p < 0.001, and HR, 3.802.76; 95% CI, 1.7726-8.156.07; P p = 
0.011, for AR CN and AR mutant, respectively) (Table 2A) and PFS (HR, 2.221.96; 95% CI, 1.4832-
3.342.93; P p <= 0.001, and HR, 2.59; 95% CI, 1.24-5.44; p = 0.012, for AR CN and AR mutant, 
respectively) (Table 2B). 
 
Plasma AR status in the PREMIERE Cohort 
The PREMIERE trial enrolled 98 patients in 16 sites between February 2015 through November 2015. 
Plasma was collected at study entry before starting enzalutamide from 94 patients who had a median 
follow-up of 10.6 months. Patient characteristics by plasma AR status are described in Table 3A.  
 
Plasma AR Associates with Worse Outcome in the PREMIERE Cohort 
Similar to our primary cohort pre-chemotherapy population, we observed AR gain in 11 (12%) patients. 
CTCs were detected in 35 patients (37%). AR gain was detected in seven (20%) CTC-positive and four 
(7%) CTC-negative patients (Table 3A). Plasma AR gain was significantly associated with shorter sPFS 
(median, 3.60 versus 15.5 months; HR, 4.33; 95% CI, 1.94-9.68; p < 0.001) (Figure 2A), rPFS (median, 
3.90 months versus not reached; HR, 8.06; 95% CI, 3.26-19.93; p < 0.001) (Figure 2B) and OS 
(medians not reached; HR, 11.08; 95% CI, 2.16-56.95; P = 0.004) (Figure 2C) (Supplementary Table 
S5, available at Annals of Oncology online). Patients with AR gain were less likely to have a ≥50% 
decline in PSA (OR, 4.93; 95% CI, 1.30-18.75; p = 0.025) (Figure 2D).  
 
Plasma AR Independently Associates with Worse Outcome on Multivariate Analysis in the 
PREMIERE Cohort 
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On multivariate analysis, the association of AR gain with the primary endpoint of sPFS was 
independent of plasma DNA concentration and the detection of CTCs (HR, 4.32; 95% CI 1.90-9.85; p < 
0.001) (Table 3B). AR gain was also independently associated on multivariate analysis with rPFS (HR, 
5.63; 95% CI, 2.15-14.74; p < 0.001) (Table 3B). 
 
 
DISCUSSION 
Several treatments are available for metastatic CRPC but to date, no approved biomarker to 
personalize therapy. Our analyses of plasma from 265 patients collected in three prospective biomarker 
protocols show that detection of AR CN gain prior to starting enzalutamide or abiraterone is associated 
with decreased OS and PFS regardless of prior chemotherapy status. We excluded samples from 
patient that had prior treatment with enzalutamide or abiraterone, given response rates and duration of 
benefit are very different when used sequentially [27]. Our previous study [8] suggests a similar 
association between plasma AR and resistance in patients previously treated with enzalutamide or 
abiraterone and this requires further investigation in future studies.  
 
We find thatdid not detect AR mutations (p.T878A or p.L702H) are uncommon in chemotherapy-naïve 
patients and p.L702H is only detected in patients previously treated with prednisone. Our assay detects 
point mutations present in at least 2% of plasma DNA. Greater sensitivity is obtained with higher input 
DNA [286] although the clinical relevance of rarer mutations is uncertain. BCritically by using a multiplex 
ddPCR with four carefully selected reference genes, we have designed a robust assay that does not 
over-call gain due to loss in regions involving the reference gene. Our model for estimating the 
likelihood of the AR CN cut-off that best predicts associations with outcome was built with 171 patients. 
We plan to perform a meta-analysis of multiple trials when the data on AR CN acquired from different 
institutions and trials exceeds 1000 patients. We report the absence of an interaction between AR and 
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chemotherapy status in non-randomized cohorts. Randomization between docetaxel and AR targeting 
agents could be challenging without pre-defined molecular selection so we here used cohorts of post-
docetaxel patients treated prior to marketing approval of abiraterone or enzalutamide for 
chemotherapy-naïve CRPC.  
 
Detection of AR splice variants in CTCs is also associated with shorter PFS and OS with enzalutamide 
or abiraterone [19, 29].  AR CN is higher in the population with detectable CTCs although AR gain can 
also be observed in CTC-negative patients, accounting for one third of AR gained in the PREMIERE 
cohort. The overlap between AR-V7 positive and plasma AR gained patients and a comparison of the 
two tests in prospective trials is warranted to develop the best biomarker strategy for identifying 
resistant patients. Testing plasma AR status by ddPCR is affordable and can be widely implemented in 
clinical laboratories but does not control for plasma DNA tumor content [7, 8] that may introduce a bias. 
Nonetheless, multivariate analyses confirm that plasma AR by ddPCR provides information on the 
outcome of men starting enzalutamide or abiraterone that is independent of other factors previously 
reported to be prognostic including serum LDH and CTC detection [25, 26, 30].  In keeping with higher 
response rates to AR targeting in chemotherapy-naïve patients, the prevalence of plasma AR 
aberrations is 10-15% in this setting compared to 30-40% post-docetaxel. As our study is single arm, 
the associations we report are prognostic although the association with PSA decline rate suggests 
Overall, our analyses provide strong supportive evidence for the role of plasma AR CN could for 
identifying patients resistant to enzalutamide or abiraterone. The aims of our study were defined after 
sample collection and therefore larger studies with a pre-specified primary objective of defining the 
association with outcome by plasma AR status could provide further supportive evidence for the role of 
AR CN as a biomarker in CRPC. Our results in patients at development of castration resistance 
suggest a role for plasma AR to select patients for taxane chemotherapy or alternative novel agents in 
preference to standard AR targeting at a key decision point in the treatment pathway., despite the 
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retrospective design of the study and the small number of patients showing AR aberrations, especially 
in chemotherapy-naïve patient group. FFor level one evidence to change clinical practice, our findings 
now require confirmation in prospective larger trials where plasma AR CN defines treatment selection. 
In addition, larger studies with pre-specified primary objectives could significantly evidence the role of 
AR CN as biomarker of resistance to anti-AR therapies. 
 
 
Legend to figures 
 
Figure 1. Association of plasma AR status and outcome in the primary cohort. Overall and 
progression-free survival for AR copy number normal, gain and mutated (Mut, p.L702H or p.T878A) 
chemotherapy-naïve (A, C) and post-docetaxel (B, D) castration-resistant prostate cancer patients 
treated with enzalutamide or abiraterone. PSA declines by AR status, waterfall plots of PSA declines for 
AR copy number normal, gain and mutated (Mut, p.L702H or p.T878A) chemotherapy-naïve (E) and 
post-docetaxel (F) castration-resistant prostate cancer patients. Bars were clipped at maximum 100%. 
 
Figure 2. Association of plasma AR status and outcome in PREMIERE cohort. Biochemical 
progression-free survival (A), radiographic progression-free survival (B) and overall survival (C) for AR 
copy number normal versus AR gain patients. Waterfall plot (D) showing the magnitude of PSA decline 
by AR status. Bars were clipped at maximum 100%.  
Page 58 of 64Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 17
Key Message 
There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistance 
prostate cancer (CRPC). This is particularly important in chemotherapy-naïve CRPC, where no 
biomarker is available and biopsies can be challenging. Following a well predefined road-map for 
biomarker development, we aimed to clinically qualify androgen receptor (AR) status measurement in 
plasma DNA using an optimized multiplex droplet digital PCR (ddPCR) assay that includes four 
carefully selected reference genes and prevents to overcall gain due to loss in regions covered by the 
reference genes. Overall, 265 CRPC patients were studied in two cohorts: the primary cohort included 
73 chemotherapy-naïve and 98 post-docetaxel patients treated with abiraterone or enzalutamide and 
independently recruited to two biomarker protocols at the Royal Marsden (UK) and IRST (Italy) 
between January 2011 and June 2016; the second cohort was composed of 94 asymptomatic or oligo-
symptomatic chemotherapy-naïve patients recruited between February and November 2015 to the 
PREMIERE trial (NCT02288936), a Spanish Oncology Genitourinary Group (SOGUG) sponsored trial 
involving 16 Spanish hospitals. In the primary cohort, AR gain was observed in 10 (14%) 
chemotherapy-naïve and 33 (34%) post-docetaxel patients and was associated with a worse OS 
(Hazard Ratio (HR), 3.98; 95% CI, 1.74-9.10; p<0.001 and HR, 3.81; 95% CI, 2.28-6.37; p<0.001 
respectively), PFS (HR, 2.18; 95% CI, 1.08-4.39; p=0.03, and HR, 1.95; 95% CI 1.23-3.11; p=0.01 
respectively) and rate of PSA decline ≥50% (Odds ratio (OR), 4.7; 95% CI, 1.17-19.17; p=0.035 and 
OR, 5.0; 95% CI, 1.70-14.91; p=0.003 respectively). AR mutations (2105T>A (p.L702H) and 2632A>G 
(p.T878A)) were observed in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-
treated patients and were also associated with worse OS (HR 3.26; 95% CI, 1.47-not reached; 
p=0.004). There was no interaction between AR and docetaxel status (p=0.83 for OS, p=0.99 for PFS). 
In the PREMIERE trial, 11 patients (12%) had AR gain that had worse sPFS (HR, 4.33; 95% CI 1.94-
9.68;  <0.001), rPFS (HR, 8.06; 95% CI, 3.26-19.93; p<0.001) and OS (HR, 11.08; 95% CI, 2.16-56.95; 
p=0.004). Plasma AR was an independent predictor of outcome on multivariate analyses in both 
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cohorts. In conclusion, detection in plasma of AR aberrations, using a robust multiplex ddPCR method, 
predicts an adverse outcome in chemotherapy-naïve and post-docetaxel CRPCThere is an urgent need 
to identify biomarkers to guide personalized therapy in CRPC. We clinically qualified androgen receptor 
(AR) status in plasma DNA using an optimized multiplex droplet digital PCR assay. We studied a 
primary cohort of 171 pre- and post-docetaxel patients treated with abiraterone or enzalutamide and a 
second cohort of 94 chemotherapy-naïve patients treated with enzalutamide, showing that detection of 
plasma AR aberrations predicted an adverse outcome in pre- and post-docetaxel CRPC.  
 
Acknowledgements 
We would like to acknowledge all the staff at SOGUG for their support to run the PREMIERE trial and 
APICES for data management. We are grateful to Astellas for supporting the PREMIERE trial. We 
thank the participating men and their families who suffered from metastatic prostate cancer and 
nonetheless gave the gift of participation so that others might benefit. 
 
Funding/Support 
This work was funded by Prostate Cancer UK (PG12-49) and Cancer Research UK (A13239) and was 
supported by the NIHR Royal Marsden and the Institute of Cancer Research (ICR) Biomedical 
Research Centre. V.C. was funded by a European Society of Medical Oncology Translational Clinical 
Research Fellowship, A.J. by an Irish Health Research Board Clinical Research Fellowship and a 
Medical Research Council Clinical Research Fellowship, D.G.T. by a European Union Marie Curie 
Intra-European Postdoctoral Fellowship, E.G.B. by a Spanish Society of Medical Oncology 
(SEOM)/Chris Foundation grant and G.A. by a Cancer Research UK Advanced Clinician Scientist 
Fellowship. The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The PREMIERE trial was sponsored by SOGUG that received a 
grant from Astellas to support the conduct of the trial. 
Page 60 of 64Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 19
The funders of the study had no role in study design, data collection, data analysis, data interpretation, 
or writing of the report. The PREMIERE trial was sponsored by SOGUG that received a grant from 
Astellas to support the conduct of the trial. The corresponding authors had full access to all data and 
had the final responsibility for the decision to submit for publication. 
 
 
Acknowledgements 
This work was funded by Cancer Research UK (A13239) and Prostate Cancer UK (PG12-49) and was 
supported by the NIHR Royal Marsden and the Institute of Cancer Research (ICR) Biomedical 
Research Centre. V.C. was funded by a European Society of Medical Oncology Translational Clinical 
Research Fellowship, A.J. by an Irish Health Research Board Clinical Research Fellowship and a 
Medical Research Council Clinical Research Fellowship, D.G.T. by a European Union Marie Curie 
Intra-European Postdoctoral Fellowship, E.G.B. by a Spanish Society of Medical Oncology 
(SEOM)/Chris Foundation grant and G.A. by a Cancer Research UK Advanced Clinician Scientist 
Fellowship. We would like to acknowledge all the staff at SOGUG for their support to run the 
PREMIERE trial and APICES for data management. We are grateful to Astellas for supporting the 
PREMIERE trial. We thank the participating men and their families who suffered from metastatic 
prostate cancer and nonetheless gave the gift of participation so that others might benefit.  
 
 
Disclosure 
The ICR developed abiraterone and therefore has a commercial interest in this agent. D.D. and G.A. 
are on the ICR list of rewards to inventors for abiraterone. G.A. has received honoraria, consulting fees, 
or travel support from Astellas, Medivation, Janssen, Millennium Pharmaceuticals, Ipsen, Ventana, 
ESSA Pharmaceuticals, and Sanofi-Aventis and grant support from Janssen, AstraZeneca, and Arno. 
Page 61 of 64 Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 20
V.C., E.G., A.F., S.V.E., A.G., B.M., O.F.C., M.M.V., M.A.C., I.D., E.G., A.Rod., C.S., M.S., J.P., U.D. 
and E.G.B. received speaker honoraria or travel support from Astellas, Janssen-Cilag and Sanofi- 
Aventis. The other authors have no conflicts to declare. 
 
  
Page 62 of 64Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 21
REFERENCES 
1. Ryan CJ, Smith, MR de Bono JS et al. Abiraterone in metastatic prostate cancer without 
previous chemotherapy. N Engl J Med 2013; 368: 138-148. 
2. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before 
chemotherapy. N Engl J Med 2014; 371: 424-433. 
3. Taniguchi K, Uchida J, Nishino K et al. Quantitative detection of EGFR mutations in circulating 
tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011; 17: 7808-7815. 
4. Dawson SJ, Tsui DW, Murtaza M et al. Analysis of circulating tumor DNA to monitor metastatic 
breast cancer. N Engl J Med 2013; 368: 1199-1209. 
5. Gevensleben H, Garcia-Murillas I, Graeser MK et al. Noninvasive detection of HER2 
amplification with plasma DNA digital PCR. Clin Cancer Res 2013; 19: 3276-3284. 
6. Tabernero J, Lenz HJ, Siena S et al. Analysis of circulating DNA and protein biomarkers to 
predict the clinical activity of regorafenib and assess prognosis in patients with metastatic 
colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 
2015; 16: 937-948. 
7. Carreira S, Romanel A, Goodall E et al. Tumor clone dynamics in lethal prostate cancer. Sci 
Transl Med 2014; 6:254ra125. 
8. Romanel A, Gasi Tandefelt D, Conteduca V et al. Plasma AR and abiraterone-resistant 
prostate cancer. Sci Transl Med 2015; 312:312re10. 
9. Salvi S, Casadio V, Conteduca V et al. Circulating cell-free AR and CYP17A1 copy number 
variations may associate with outcome of metastatic castration-resistant prostate cancer 
patients treated with abiraterone. Br J Cancer 2015; 112: 1717-1724. 
10. Salvi S, Casadio V, Conteduca V et al. Circulating AR copy number and outcome to 
enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget 
2016; 7: 37839-37845. 
Page 63 of 64 Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 22
11. Azad AA, Volik SV, Wyatt AW et al. Androgen receptor gene aberrations in circulating cell-free 
DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer 
Res 2015; 21: 2315-2324.  
12. Wyatt AW, Azad AA, Volik SV et al. Genomic alterations in cell-free DNA and enzalutamide 
resistance in castration-resistant prostate cancer. JAMA Oncol 2016; 2: 1598-1606. 
13. Kumar A, Coleman I, Morrissey C et al. Substantial interindividual and limited intraindividual 
genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 2016; 22: 
369-378. 
14. Chen EJ, Sowalsky AG, Gao S et al. Abiraterone treatment in castration-resistant prostate 
cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res 2015; 
21: 1273-1280. 
15. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic 
androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-1398. 
16. Balbas MD, Evans MJ, Hosfield DJ et al. Overcoming mutation-based resistance to 
antiandrogens with rational drug design. Elife. 2013; 2:e00499. 
17. Joseph JD, Lu N, Qian J et al. A clinically relevant androgen receptor mutation confers 
resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 
2013; 3: 1020-1029. 
18. http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@fre/@fun/documents/ge
neralcontent/cr_027486.pdf 
19. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in 
prostate cancer. N Engl J Med 2014; 371: 1028-1038. 
20. Attard G, de Bono JS, Logothetis CJ et al. Improvements in Radiographic Progression-Free 
Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer 
Patients Treated with Abiraterone Acetate. Clin Cancer Res 2015; 21: 1621-1627. 
Page 64 of 64Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 23
21. Grande E, Fernandez-Perez MP, Font A et al. Early responses to enzalutamide in AR-V7 
positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective 
SOGUG clinical trial: The PREMIERE study. Ann Oncol 2016; 27(Suppl 6): vi243-vi265. 
22. Scher HI, Halabi S, Tannock I et al. Prostate Cancer Clinical Trials Working Group. Design and 
end points of clinical trials for patients with progressive prostate cancer and castrate levels of 
testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin 
Oncol 2008; 26: 1148-1159. 
23. R Core Team, 2015. R. A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria. URL https://www.R-project.org/  
24. Mazumdar M, Smith A, Bacik J. Methods for categorizing a prognostic variable in a 
multivariable setting. Stat Med 2003; 22: 559-571. 
25. Chi KN, Kheoh T, Ryan CJ et al. A prognostic index model for predicting overall survival in 
patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate 
after docetaxel. Ann Oncol 2016; 27: 454-460. 
26. Halabi S, Lin CY, Kelly WK et al. Updated prognostic model for predicting overall survival in 
first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin 
Oncol 2014; 32: 671-677. 
27. Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing of agents in castration-
resistant prostate cancer. Lancet Oncol 2015; 16: e279-e292. 
28. Hindson BJ, Ness KD, Masquelier DA et al. High-throughput droplet digital PCR system for 
absolute quantitation of DNA copy number. Anal Chem 2011; 83: 8604-8610. 
29. Scher HI, Lu D, Schreiber NA et al. Association of AR-V7 on circulating tumor cells as a 
treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. 
JAMA Oncol 2016; 2: 1441-1449. 
Page 65 of 64 Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 24
30. Scher HI, Heller G, Molina A et al. Circulating tumor cell biomarker panel as an individual-level 
surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 2015; 33: 
1348-1355.  
 
Page 66 of 64Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
